Vistagen Therapeutics Inc Revenue Growth Rates (VTGN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vistagen Therapeutics Inc   (NASDAQ: VTGN)
 

VTGN's Revenue Growth by Quarter and Year

Vistagen Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/VTGN/growth
https://api.csimarket.com/api/v1/companies/VTGN/fundamentals
https://api.csimarket.com/api/v1/companies/VTGN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
VTGN Revenue (in millions $) FY 2027 FY 2026 FY 2025 FY 2024
4th Quarter March -
3rd Quarter December -
2nd Quarter September 0.14
1st Quarter June 1.48
FY 1.62

VTGNs Annual Revenue
Vistagen Therapeutics Inc 's Revenue in the fiscal year 2026 $ 1.27 millions
Vistagen Therapeutics Inc 's Revenue in the fiscal year 2025 $ 0.49 millions
Vistagen Therapeutics Inc 's Revenue in the fiscal year 2024 $ 1.06 millions
Vistagen Therapeutics Inc 's Revenue in the fiscal year 2023 $ 0.23 millions
Vistagen Therapeutics Inc 's Revenue in the fiscal year 2022 $ 1.11 millions




VTGN Revenue second quarter 2027 Y/Y Growth Comment
Vistagen Therapeutics Inc reported drop in Revenue in the second quarter 2027 by -46.92% to $ 0.14 millions, from the same quarter in 2026.
The fall in the second quarter 2027 Vistagen Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue decline of -19.5%.

Looking into second quarter 2027 results within Major Pharmaceutical Preparations industry 57 other companies have achieved higher Revenue growth. While Vistagen Therapeutics Inc ' s Revenue meltdown of -46.92% ranks overall at the positon no. 506 in the second quarter 2027.


VTGN Revenue ( Y/Y Growth %) 2027
 FY 2026 FY 2025 FY 2024
4th Quarter March -
3rd Quarter December -
2nd Quarter September -46.92 %
1st Quarter June 516.67 %
FY   -

Financial Statements
Vistagen Therapeutics Inc 's second quarter 2027 Revenue $ 0.14 millions VTGN's Income Statement
Vistagen Therapeutics Inc 's second quarter 2026 Revenue $ 0.26 millions Quarterly VTGN's Income Statement


VTGN Revenue (Quarter on Quarter Growth %)

 2027
 FY 2026 FY 2025 FY 2024
4th Quarter March -
3rd Quarter December -
2nd Quarter September -90.68 %
1st Quarter June 221.74 %
FY (Year on Year)   -


Back to VTGN Growth rate Comparisons >> Back to VTGN Growth rate Comparisons >>


Revenue second quarter 2027 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #122
Overall #506

Revenue Y/Y Growth Statistics
High Average Low
287.15 % -19.5 % -133.8 %
(Jun 30 2026)   (Jun 30 2023)
Revenue second quarter 2027 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #122
Overall #506
Revenue Y/Y Growth Statistics
High Average Low
287.15 % -19.5 % -133.8 %
(Jun 30 2026)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2024, 2025, 2026, 2027

Vistagen Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
19730.87 % 703.4 % -100 %
(Mar 31 2012)  


VTGN's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2027 Vistagen Therapeutics Inc disclosed fall in Revenue from the first quarter by -90.68% to $ 0.14 millions, from $ 1.48 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2027 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 19 other companies have achieved higher Revenue quarter on quarter growth. While Vistagen Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 86.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #32
Overall #86
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #32
Overall #86
Revenue Q/Q Growth Statistics
High Average Low
19730.87 % 703.4 % -100 %
(Mar 31 2012)  


VTGN's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2027 Vistagen Therapeutics Inc disclosed fall in Revenue from the first quarter by -90.68% to $ 0.14 millions, from $ 1.48 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2027 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 19 other companies have achieved higher Revenue quarter on quarter growth. While Vistagen Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 86.


Vistagen Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 2.50
Y / Y Revenue Growth (TTM) 287.15 %
Year on Year Revenue Growth Overall Ranking # 3512
Seqeuential Revenue Change (TTM) 97.08 %
Seq. Revenue Growth (TTM) Overall Ranking # 506


Cumulative Revenue growth Comment
With 287.15% annual Revenue growth, Vistagen Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 476 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3218 to 3512.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 477
Overall # 3512

Revenue TTM Y/Y Growth Statistics
High Average Low
287.15 %
 -19.5 %
-133.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 122
S&P 500 # 506
Cumulative Revenue growth Comment
With 287.15% annual Revenue growth, Vistagen Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 476 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3218 to 3512.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 477
Overall # 3512

Revenue TTM Y/Y Growth Statistics
High Average Low
287.15 %
-19.5 %
-133.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 122
S&P 500 # 506




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VTGN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Sutro Biopharma Inc -6.14%$ -6.138 millions


About Vistagen Therapeutics Inc Revenue Growth Rates (VTGN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vistagen Therapeutics Inc (CIK 1411685).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-057116
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vistagen Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.